{"id":"pralatrexate-injection","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Mucositis"},{"rate":"25-35","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"20-30","effect":"Neutropenia"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-25","effect":"Fatigue"},{"rate":"10-20","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL1201746","moleculeType":"Small molecule","molecularWeight":"477.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pralatrexate is a 10-deazaaminopterin derivative that acts as an antifolate agent. It preferentially enters cells via the folate receptor and reduced folate carrier, then inhibits key enzymes in one-carbon metabolism including dihydrofolate reductase, leading to depletion of nucleotides and cell cycle arrest. This mechanism makes it particularly effective against rapidly dividing malignant cells.","oneSentence":"Pralatrexate is a folate analog that inhibits dihydrofolate reductase and other folate-dependent enzymes, disrupting DNA synthesis and cell division in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:46.791Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"},{"name":"Relapsed or refractory T-cell lymphomas"}]},"trialDetails":[{"nctId":"NCT07036133","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","startDate":"2022-12-28","conditions":"Advanced Solid Tumors, Hematologic Malignancies","enrollment":24},{"nctId":"NCT06072131","phase":"PHASE3","title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","startDate":"2023-10-04","conditions":"Peripheral T Cell Lymphoma","enrollment":504},{"nctId":"NCT01420679","phase":"PHASE3","title":"Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2011-08","conditions":"Peripheral T-cell Lymphoma","enrollment":21},{"nctId":"NCT00998946","phase":"PHASE2","title":"Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2009-09","conditions":"Lymphoma, B-Cell","enrollment":29},{"nctId":"NCT02594267","phase":"PHASE1","title":"A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2015-11-10","conditions":"Peripheral T-Cell Lymphoma (PTCL)","enrollment":48},{"nctId":"NCT00606502","phase":"PHASE2","title":"Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2008-01","conditions":"Non-small Cell Lung Cancer","enrollment":201},{"nctId":"NCT01118624","phase":"PHASE2","title":"Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-03","conditions":"Breast Cancer, Breast Tumors, Neoplasms, Breast","enrollment":22},{"nctId":"NCT00481871","phase":"PHASE1, PHASE2","title":"Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2007-05","conditions":"Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma","enrollment":119},{"nctId":"NCT00554827","phase":"PHASE1","title":"Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2007-08","conditions":"Cutaneous T-cell Lymphoma","enrollment":55},{"nctId":"NCT00364923","phase":"PHASE2","title":"Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2006-08","conditions":"Peripheral T-cell Lymphoma","enrollment":115},{"nctId":"NCT01134341","phase":"PHASE1","title":"Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2010-03","conditions":"Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome","enrollment":34},{"nctId":"NCT00722553","phase":"PHASE2","title":"Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2008-07","conditions":"Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm","enrollment":30},{"nctId":"NCT02106650","phase":"PHASE2","title":"Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","startDate":"2014-07","conditions":"Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma","enrollment":36},{"nctId":"NCT01188876","phase":"PHASE1, PHASE2","title":"Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":50},{"nctId":"NCT02013362","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Mundipharma K.K.","startDate":"2014-03","conditions":"Peripheral T-cell Lymphoma","enrollment":25},{"nctId":"NCT01183065","phase":"PHASE2","title":"Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-08","conditions":"Head and Neck Cancer","enrollment":13}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"STOMATITIS"},{"count":6,"reaction":"PLATELET COUNT DECREASED"},{"count":4,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":3,"reaction":"ANAEMIA"},{"count":3,"reaction":"LYMPHOPENIA"},{"count":3,"reaction":"MUCOSAL INFLAMMATION"},{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"FALL"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Folotyn®","FOLOTYN","PDX","Pralatrexate","(RS)-10-propargyl-10-deazaaminopterin"],"phase":"phase_3","status":"active","brandName":"Pralatrexate injection","genericName":"Pralatrexate injection","companyName":"Mundipharma K.K.","companyId":"mundipharma-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pralatrexate is a folate analog that inhibits dihydrofolate reductase and other folate-dependent enzymes, disrupting DNA synthesis and cell division in rapidly dividing cells. Used for Peripheral T-cell lymphoma (PTCL), Relapsed or refractory T-cell lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}